A Randomized, placebo controlled study to determine the effect of two dose schedules of R1507 or placebo, both in combination with erlotinib (Tarceva®), on progression-free survival in patients with advanced non-small cell lung cancer with disease progression after first or second line chemotherapy

Phase 1

• Conditions: To investigate in a randomized fashion if the addition of targeted IGF-1R blockade with R1507 has additional clinical benefit when combined with erlotinib in patients with advanced NSCLC who have failed at least one, but no more than two standard chemotherapy regimens. The study will also investigate 2 doses and schedules of R1507 combined with erlotinib compared with erlotinib and placebo, and assess the safety and tolerability of the combination in this patient population.; MedDRA version: 13.1 Level: PT Classification code 10029522 Term: Non-small cell lung cancer stage IV System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps); MedDRA version: 13.1 Level: PT Classification code 10029521 Term: Non-small cell lung cancer stage IIIB System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

• Registration Number: EUCTR2008-001736-12-GB
• Lead Sponsor: F. Hoffmann-La Roche Ltd

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2008-10-22
• Study Completion: 2010-06-14
• Last Update Posted: 25 November 2019

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: Not specified
• Target Recruitment: 150

Inclusion Criteria

1. Male and female patients, age =18 years
2. Able to comply with the protocol
3. Patients must be able to take oral medication
4. Histologically documented inoperable, locally advanced or metastatic (stage IIIB and stage IV) NSCLC. (NOTE: Sputum cytology alone is not acceptable). Tumors with
mixed histology should be categorized according to the predominant cell type
5. Prior Treatment: Failed at least one, but no more than two standard chemotherapy regimens
6. Patients who have received maintenance chemotherapy between initial course of therapy (first line) and study entry may enter on the study provided they have not been treated with an agent that targets EGFR or IGF-1R
7. Formalin fixed paraffin embedded tumor tissue samples from initial or subsequent diagnosis representative of the disease must be available for shipment to Roche prior to randomization
8. Measurable disease according to RECIST
9. ECOG performance status 0-2
10. Life expectancy > 12 weeks
11. Adequate hematological function : ANC =1.5 x 10 exp9/L; platelets =100 x 10 exp9/L, Hb =9 g/dL
12. INR =1.5 and PTT =1.5 x ULN unless receiving anticoagulant therapy
13. Adequate liver function: Serum bilirubin =1.5 x ULN; transaminases =2.5 x ULN (in case of liver metastases <5 x ULN)
14. Adequate renal function: Serum creatinine = 1.5 X ULN
15. Serum calcium = 1.1 X ULN
16. HbA1c = 7%
17. Negative pregnancy test within 7 days of starting study treatment in pre-menopausal women and women < 2 years after the onset of menopause
18. Signed informed consent
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

1. Patients must have had a head CT/MRI to evaluate for CNS metastasis within 28 days prior to enrollment. Patients with active CNS lesions are excluded. Patients with
radiographically stable, asymptomatic previously irradiated lesions are eligible provided patients is = 4 weeks beyond completing cranial irradiation and = 3 weeks off corticosteroid therapy
2. Prior treatment with an investigational or commercial agent that acts via IGF-1R inhibition
3. Prior treatment with an agent that acts via EGFR targeting
4. Administration of any anti-cancer therapies other than those administered in this study during protocol treatment
5. Administration of high doses of systemic corticosteroids. High dose is considered as > 1 mg/kg per day of prednisone(or equivalent)for more than 7 consecutive days.
Dexamethasone may induce CYP3A4 activity. CYP3A4 inhibitors and inducers may influence the plasma level of erlotinib
6. Prior irradiation: 1) Radiotherapy given within the last 4 weeks prior to first dose of study treatment. 2) Palliative radiotherapy for bone lesions outside the thoracic region within 2 weeks prior to the first dose of study treatment
7. Prior Surgery: Surgery (including open biopsy) or significant traumatic injury within the last 2 weeks prior to first dose of study treatment or anticipation of the need for
major surgery during study treatment. Patients who undergo minor surgical procedures (for example, placement of a central venous access device) must be sufficiently recovered from the procedure to receive chemotherapy but do not require a mandatory 14 day interval between the procedure and initiation of study treatment.
8. Patients who have not recovered from adverse events to = grade 1, (excluding alopecia) from previously administered therapies and must be randomly assigned to study treatment at least 21 days after chemotherapy (14 days after treatment with vinca alkaloids or gemcitabine)
9. Lactating women
10. Fertile men or women of childbearing potential not using effective methods to prevent pregnancy throughout the trial and for 90 days after last study administration in both sexes. Women of childbearing potential must have a negative pregnancy test (serum ß-HCG) within the 7 days prior to study drug administration.
NOTE: Women of childbearing potential includes both pre-menopausal women and women within the first 2 years of the onset of menopause.
NOTE: Effective methods of birth control includes surgically sterile, barrier device (condom, diaphragm), contraceptive coil, abstinence. Oral contraceptive pills (OCPs) alone are not considered an effective method.
11. Other active cancer requiring treatment
12. Known hypersensitivity to any of the study drugs or their excipients
13. Any disease (including psychotic disorders, drug abuse, active infection, uncontrolled hypertension, clinically significant cardiovascular disease for example CVA (= 6 months before randomization), myocardial infarction (= 6 months before randomization), unstable angina, NYHA = grade 2 CHF, arrhythmia requiring medication, hepatic, renal or metabolic disease (including uncontrolled diabetes
mellitus), metabolic dysfunction, physical examination find

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified